VanEck Associates’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.94M | Sell |
26,210
-10,616
| -29% | -$1.89M | ﹤0.01% | 791 |
|
|
2026
Q1 | $6.35M | Buy |
36,826
+1,325
| +4% | +$246K | ﹤0.01% | 740 |
|
|
2025
Q4 | $7.08M | Sell |
35,501
-3,289
| -8% | -$597K | 0.01% | 671 |
|
|
2025
Q3 | $6.07M | Sell |
38,790
-5,736
| -13% | -$911K | 0.01% | 697 |
|
|
2025
Q2 | $6.76M | Sell |
44,526
-1,724
| -4% | -$230K | 0.01% | 612 |
|
|
2025
Q1 | $6.96M | Sell |
46,250
-2,130
| -4% | -$357K | 0.01% | 594 |
|
|
2024
Q4 | $8.93M | Sell |
48,380
-2,893
| -6% | -$557K | 0.01% | 498 |
|
|
2024
Q3 | $9.57M | Sell |
51,273
-6,633
| -11% | -$1.38M | 0.01% | 455 |
|
|
2024
Q2 | $12M | Buy |
57,906
+2,269
| +4% | +$514K | 0.02% | 376 |
|
|
2024
Q1 | $15.1M | Sell |
55,637
-2,042
| -4% | -$488K | 0.02% | 321 |
|
|
2023
Q4 | $13.6M | Sell |
57,679
-5,418
| -9% | -$1.07M | 0.02% | 309 |
|
|
2023
Q3 | $12.4M | Buy |
63,097
+7,461
| +13% | +$1.53M | 0.03% | 313 |
|
|
2023
Q2 | $11.7M | Buy |
55,636
+2,387
| +4% | +$475K | 0.03% | 321 |
|
|
2023
Q1 | $10.7M | Sell |
53,249
-7,950
| -13% | -$1.8M | 0.02% | 337 |
|
|
2022
Q4 | $13.3M | Buy |
61,199
+15,893
| +35% | +$3.47M | 0.03% | 293 |
|
|
2022
Q3 | $8.92M | Sell |
45,306
-15,778
| -26% | -$3.41M | 0.03% | 333 |
|
|
2022
Q2 | $13.1M | Buy |
61,084
+4,305
| +8% | +$1.05M | 0.03% | 291 |
|
|
2022
Q1 | $16.1M | Buy |
56,779
+253
| +0.4% | +$78K | 0.03% | 289 |
|
|
2021
Q4 | $21.3M | Sell |
56,526
-4,076
| -7% | -$1.58M | 0.05% | 246 |
|
|
2021
Q3 | $25M | Sell |
60,602
-11,399
| -16% | -$4.73M | 0.06% | 225 |
|
|
2021
Q2 | $26.6M | Buy |
72,001
+5,757
| +9% | +$1.92M | 0.06% | 223 |
|
|
2021
Q1 | $19.2M | Sell |
66,244
-5,255
| -7% | -$1.46M | 0.05% | 235 |
|
|
2020
Q4 | $17.9M | Buy |
71,499
+6,915
| +11% | +$1.65M | 0.05% | 218 |
|
|
2020
Q3 | $14.6M | Sell |
64,584
-13,522
| -17% | -$2.81M | 0.05% | 215 |
|
|
2020
Q2 | $13.6M | Buy |
78,106
+17,569
| +29% | +$2.8M | 0.05% | 217 |
|
|
2020
Q1 | $7.64M | Sell |
60,537
-15,455
| -20% | -$2.32M | 0.04% | 254 |
|
|
2019
Q4 | $11.6M | Buy |
75,992
+1,016
| +1% | +$141K | 0.04% | 235 |
|
|
2019
Q3 | $9.93M | Buy |
74,976
+1,814
| +2% | +$243K | 0.05% | 220 |
|
|
2019
Q2 | $10.4M | Sell |
73,162
-13,803
| -16% | -$1.87M | 0.05% | 223 |
|
|
2019
Q1 | $12.6M | Sell |
86,965
-13,974
| -14% | -$1.84M | 0.06% | 200 |
|
|
2018
Q4 | $11.4M | Buy |
100,939
+6,782
| +7% | +$849K | 0.06% | 213 |
|
|
2018
Q3 | $12.7M | Buy |
94,157
+481
| +0.5% | +$59.4K | 0.06% | 225 |
|
|
2018
Q2 | $10.5M | Buy |
93,676
+13,291
| +17% | +$1.44M | 0.05% | 230 |
|
|
2018
Q1 | $8.58M | Sell |
80,385
-19,168
| -19% | -$2.07M | 0.04% | 242 |
|
|
2017
Q4 | $10.9M | Sell |
99,553
-53,924
| -35% | -$5.87M | 0.05% | 226 |
|
|
2017
Q3 | $16.6M | Buy |
153,477
+5,195
| +4% | +$534K | 0.08% | 189 |
|
|
2017
Q2 | $15M | Buy |
148,282
+17,097
| +13% | +$1.57M | 0.08% | 190 |
|
|
2017
Q1 | $11.8M | Buy |
131,185
+7,228
| +6% | +$614K | 0.05% | 218 |
|
|
2016
Q4 | $9.44M | Sell |
123,957
-753
| -0.6% | -$57.2K | 0.05% | 234 |
|
|
2016
Q3 | $10.4M | Sell |
124,710
-18,872
| -13% | -$1.58M | 0.05% | 207 |
|
|
2016
Q2 | $11.8M | Buy |
143,582
+16,186
| +13% | +$1.33M | 0.06% | 186 |
|
|
2016
Q1 | $9.67M | Buy |
127,396
+7,389
| +6% | +$547K | 0.07% | 175 |
|
|
2015
Q4 | $9.65M | Buy |
120,007
+3,253
| +3% | +$235K | 0.08% | 184 |
|
|
2015
Q3 | $7.42M | Sell |
116,754
-18,947
| -14% | -$1.36M | 0.06% | 199 |
|
|
2015
Q2 | $9.54M | Buy |
135,701
+11,542
| +9% | +$854K | 0.06% | 213 |
|
|
2015
Q1 | $9.85M | Buy |
124,159
+113
| +0.1% | +$8.34K | 0.06% | 208 |
|
|
2014
Q4 | $7.89M | Buy |
124,046
+4,483
| +4% | +$281K | 0.05% | 214 |
|
|
2014
Q3 | $7.14M | Sell |
119,563
-6,511
| -5% | -$373K | 0.04% | 214 |
|
|
2014
Q2 | $6.75M | Sell |
126,074
-28,760
| -19% | -$1.58M | 0.03% | 224 |
|
|
2014
Q1 | $9.34M | Buy |
154,834
+25,451
| +20% | +$1.48M | 0.05% | 192 |
|
|
2013
Q4 | $6.86M | Buy |
129,383
+13,052
| +11% | +$655K | 0.03% | 211 |
|
|
2013
Q3 | $5.38M | Buy |
116,331
+2,075
| +2% | +$95.2K | 0.03% | 222 |
|
|
2013
Q2 | $4.69M | Buy |
+114,256
| New | +$4.9M | 0.03% | 225 |
|
Other funds holding CRL
AI
VanEck Associates's CRL Position: Q2 2026 in Review
VanEck Associates reduced its Charles River Laboratories (CRL) stake by 29% in Q2 2026, selling an estimated $1.89M and leaving 26,210 shares worth $5.94M. The position accounts for ﹤0.01% of the portfolio, ranked #791.
VanEck Associates first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. The position peaked at $26.6M in Q2 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- VanEck Associates held 26,210 shares of Charles River Laboratories worth $5.94M as of Q2 2026.
- VanEck Associates sold 10,616 Charles River Laboratories shares in Q2 2026, an estimated $1.89M.
- Charles River Laboratories made up ﹤0.01% of VanEck Associates's portfolio in Q2 2026, its #791 holding.
- VanEck Associates first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- VanEck Associates's Charles River Laboratories position peaked at $26.6M in Q2 2021.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.